Search
Xelaglifam
go.drugbank.com/drugs/DB21598InvestigationalXelaglifam is under investigation in clinical trial NCT04982705 (IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics). Xelaglifam has a monoisotopic molecular weight of 501.2 Da.
Diclofenamide
go.drugbank.com/drugs/DB01144ApprovedA carbonic anhydrase inhibitor that is used in the treatment of glaucoma.
Bamipine
go.drugbank.com/drugs/DB13489InvestigationalBamipine is a first-generation antihistamine.
Categories: Antihistamines for Systemic Use, Antihistamines for Topical UseRocatinlimab
go.drugbank.com/drugs/DB18809InvestigationalRocatinlimab is a subcutaneously administered anti-OX40 antibody developed for the treatment of moderate-to-severe atopic dermatitis. … The drug works by targeting the OX40 receptor, which plays a role in the immune response associated with atopic dermatitis.
Modimelanotide
go.drugbank.com/drugs/DB15314InvestigationalModimelanotide is under investigation in clinical trial NCT01897519 (A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing
Rocapuldencel-T
go.drugbank.com/drugs/DB17588InvestigationalRocapuldencel-T is an autologous dendritic cell immunotherapy that was investigated in NCT02662634 (A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
AVXS-301
go.drugbank.com/drugs/DB17943ExperimentalIt is being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).[L47077]
Biropepimut-S
go.drugbank.com/drugs/DB14816InvestigationalBiropepimut-S is under investigation in clinical trial NCT02873819 (Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral
Aspartyl-alanyl-diketopiperazine
go.drugbank.com/drugs/DB14940InvestigationalAspartyl-alanyl-diketopiperazine is under investigation in clinical trial NCT03349645 (An Open Label Extension Study to Assess the Safety of Long-Term Treatment With Ampion for Severe OA of the Knee).
EU204
go.drugbank.com/drugs/DB17438InvestigationalEU204 (EBViNT) is an Epstein-Barr virus (EBV)-positive T-cell therapy currently undergoing phase 1 and 2a clinical trials in Korea for patients with EBV-positive lymphoma and solid cancer.